Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Frederic Combemale, B.P. 307, 59020, Lille Cedex, France.
Medical Oncology Department, Oscar Lambret Center, Lille, France.
Support Care Cancer. 2018 Mar;26(3):751-758. doi: 10.1007/s00520-017-3885-3. Epub 2017 Sep 17.
The purpose of this study is to assess the efficacy of Sm-EDTMP (Quadramet®) in a clinical setting.
We have conducted a retrospective study of all consecutive patients (pts) treated with Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters.
Three hundred seventy consecutive Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases.
Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
本研究旨在评估 Sm-EDTMP（Quadramet®）在临床环境中的疗效。
我们对所有接受 Sm-EDTMP 治疗骨转移疼痛的连续患者（pts）进行了回顾性研究。在每次就诊（治疗前后）时，收集了四个参数：（i）根据 10 分视觉模拟量表（VAS）评估疼痛，（ii）与疼痛相关的睡眠障碍，（iii）止痛药物剂量，以及（iv）回答以下封闭式问题“您认为治疗对您有帮助吗？”治疗的成功定义为这四个参数的组合。
共进行了 370 例 Sm-EDTMP 治疗骨转移疼痛的连续治疗。患者的主要肿瘤如下：乳腺癌（153），前列腺癌（155），肺癌（27）或其他癌症（35）。58％的患者接受过先前的外部骨放疗。97％的患者接受了联合止痛治疗，61％的患者接受了双膦酸盐治疗。在 D30 时，55.0％的病例描述了临床获益。与其他类型的原发性癌症相比，乳腺癌和前列腺癌的治疗效果更好。在 D30 时，62％，58％，6％和 38％的乳腺癌，前列腺癌，肺癌和其他癌症患者描述了获益。35.0％的病例中，主观疗效伴随着止痛药物摄入量的减少。
Sm-EDTMP 治疗是患有骨转移的患者的有效支持性治疗方法，尤其是患有乳腺癌或前列腺癌的患者。
